+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Pancreatitis Pipeline Insight, 2019

  • ID: 4835329
  • Drug Pipelines
  • September 2019
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Amersham
  • BioLineRx
  • CalciMedica
  • ChiRhoClin
  • Cytopathfinder
  • Eisai Co Ltd
  • MORE
Acute Pancreatitis

Overview:

Acute Pancreatitis - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pancreatitis pipeline landscape is provided which includes the disease overview and Acute Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Acute Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Acute Pancreatitis Understanding

According to the National Pancreas Foundation, Acute pancreatitis is an inflammatory condition of the pancreas that is painful and at times deadly. Acute pancreatitis is an acute inflammatory condition, with a range of severity as well as various local and systemic complications. In addition to the acute form, there are hereditary and chronic forms of pancreatitis which can devastate a person over many years. Sufferers often endure pain and malnutrition, and are most likely left with a higher risk of pancreatic cancer. The onset of pancreatitis is considered to coincide with the 1st day of pain, not the day on which the patient presents for care or the day of hospital admission. Coughing, vigorous movement, and deep breathing may worsen the pain. Sitting upright and leaning forward may provide some relief. Most people feel nauseated and have to vomit, sometimes to the point of dry heaves (retching without producing any vomit). Often, even large doses of an injected opioid analgesic do not relieve pain completely.

Acute Pancreatitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Acute Pancreatitis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Acute Pancreatitis pipeline report covers 10+ companies. Some of the key players include CalciMedica (CM 4620), Samsung Bioepis (SB 26), GlaxoSmithKline (GSK 3335065) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Acute Pancreatitis Analytical Perspective

In-depth Acute Pancreatitis Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Acute Pancreatitis Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Acute Pancreatitis report provides an overview of therapeutic pipeline activity for Acute Pancreatitis across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Acute Pancreatitis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Acute Pancreatitis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acute Pancreatitis
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Acute Pancreatitis to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Acute Pancreatitis R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Acute Pancreatitis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Acute Pancreatitis to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Please note: The report will be dispatched within 2-3 days
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amersham
  • BioLineRx
  • CalciMedica
  • ChiRhoClin
  • Cytopathfinder
  • Eisai Co Ltd
  • MORE
1. Report Introduction

2. Acute Pancreatitis
2.1. Acute Pancreatitis Disease Overview
2.2. Acute Pancreatitis History
2.3. Acute Pancreatitis Symptoms
2.4. Acute Pancreatitis Causes
2.5. Acute Pancreatitis Pathophysiology
2.6. Acute Pancreatitis Diagnosis
2.6.1. Diagnostic Guidelines

3. Acute Pancreatitis Current Treatment Patterns
3.1. Treatment Guidelines

4. Acute Pancreatitis- Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Acute Pancreatitis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Acute Pancreatitis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Acute Pancreatitis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono/Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA

5. Acute Pancreatitis Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products

6. Acute Pancreatitis-Products Analysis
6.1. Product Profiles
6.1.1. CM 4620: CalciMedica
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. SB 26: Samsung Bioepis
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. GSK 3335065: GlaxoSmithKline
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table

7. Recent Technologies

8. Acute Pancreatitis Key Companies
8.1. CalciMedica
8.2. Vernalis
8.3. Eisai Co Ltd
8.4. Cytopathfinder
8.5. Samsung Bioepis
8.6. Sun BioPharma
8.7. ICOS Corporation
8.8. ChiRhoClin
8.9. Amersham
8.10. GlaxoSmithKline

9. Acute Pancreatitis Key Products
9.1. CM 4620
9.2. SB 26
9.3. GSK 3335065
9.4. CM 128
9.5. Lexipafant
9.6. Patamostat mesylate
9.7. PG 103
9.8. SBP 101
9.9. PAF-acetylhydrolase
9.10. Secretin
9.11. IT 9302

10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation

11. Acute Pancreatitis- Unmet Needs

12. Acute Pancreatitis- Future Perspectives

13. Appendix

14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • CalciMedica
  • Vernalis
  • Eisai Co Ltd
  • BioLineRx
  • Cytopathfinder
  • Samsung Bioepis
  • Sun BioPharma
  • ICOS Corporation
  • ChiRhoClin
  • Amersham
  • GlaxoSmithKline
  • NewLink Genetics Corporation
Note: Product cover images may vary from those shown
Adroll
adroll